Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

ENDRA Life Sciences (NDRA) Research & Development (2016 - 2021)

ENDRA Life Sciences (NDRA) has disclosed Research & Development for 6 consecutive years, with $1.4 million as the latest value for Q4 2021.

  • Quarterly Research & Development rose 24.43% to $1.4 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $5.5 million through Dec 2021, down 7.36% year-over-year, with the annual reading at $1.8 million for FY2025, 42.01% down from the prior year.
  • Research & Development for Q4 2021 was $1.4 million at ENDRA Life Sciences, up from $1.2 million in the prior quarter.
  • The five-year high for Research & Development was $2.0 million in Q4 2019, with the low at $95814.0 in Q1 2017.
  • Average Research & Development over 5 years is $1.2 million, with a median of $1.3 million recorded in 2017.
  • The sharpest move saw Research & Development crashed 51.82% in 2017, then skyrocketed 1641.73% in 2018.
  • Over 5 years, Research & Development stood at $1.4 million in 2017, then dropped by 22.72% to $1.1 million in 2018, then skyrocketed by 92.99% to $2.0 million in 2019, then tumbled by 43.63% to $1.1 million in 2020, then grew by 24.43% to $1.4 million in 2021.
  • According to Business Quant data, Research & Development over the past three periods came in at $1.4 million, $1.2 million, and $1.7 million for Q4 2021, Q3 2021, and Q2 2021 respectively.